We have evaluated drug retention rate and predictive factors of drug survival for interleukin-1 inhibitors in systemic juvenile idiopathic arthritis. Our findings suggest an excellent overall drug retention rate for both anakinra and canakinumab that might be further augmented by paying attention to adverse events and employing these agents as first-line biologics in an early disease phase.
|Numero di pagine||2|
|Rivista||PEDIATRIC RHEUMATOLOGY ONLINE JOURNAL|
|Volume||10th Congress of International Society of Systemic Auto-Inflammatory Diseases (ISSAID)|
|Stato di pubblicazione||Pubblicato - 2019|
- Juvenile idiopathic arthritis